GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Scaled Net Operating Assets

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Scaled Net Operating Assets : -0.22 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyclacel Pharmaceuticals's operating assets for the quarter that ended in Dec. 2023 was $5.43 Mil. Cyclacel Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2023 was $8.16 Mil. Cyclacel Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $12.50 Mil. Therefore, Cyclacel Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -0.22.


Cyclacel Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Scaled Net Operating Assets Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.06 0.03 0.05 -0.10

Cyclacel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.12 -0.02 -0.10 -0.22

Competitive Comparison of Cyclacel Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Scaled Net Operating Assets falls into.



Cyclacel Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyclacel Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(5.427-8.161)/28.05
=-0.10

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=8.805 - 3.378
=5.427

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.198 - 0.037 - 0
=8.161

Cyclacel Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(5.427-8.161)/12.497
=-0.22

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=8.805 - 3.378
=5.427

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.198 - 0.037 - 0
=8.161

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclacel Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.